<DOC>
	<DOCNO>NCT00089453</DOCNO>
	<brief_summary>The purpose study induce anti-myeloma response patient high risk relapse myeloma use combination chemo- immunotherapy comprise sequentially : 1 ) lymphoid myeloid suppressive conditioning , 2 ) adoptive transfer purify KIR-ligand mismatch Natural Killer cell haplo-identical donor , 3 ) autografting two week infusion NK cell ensure autologous reconstitution . Other objective include establish response rate , disease free survival , progression free survival toxicity regimen . Secondary objective monitor persistence haplo-identical purified KIR-ligand mismatch Natural Killer cell molecular method , select haplo-identical purify KIR-ligand mismatch donor predict prior therapy donor induce response , monitor Natural Killer cell reconstitution prior autografting , establish Natural Killer cell clone autografting determine origin specificity .</brief_summary>
	<brief_title>Study KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant</brief_title>
	<detailed_description>This study induce anti-myeloma response patient high risk relapse myeloma use combination chemo- immunotherapy comprise sequentially : 1 ) lymphoid suppressive conditioning avoid rejection donor NK cell , 2 ) adoptive transfer purify KIR-ligand mismatch Natural Killer cell haplo-identical donor , 3 ) autografting two week infusion NK cell ensure autologous reconstitution .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>MM frank relapse single tandem transplant high risk Myeloma Patients prior transplant must 4 month last transplant Karnofsky performance score &gt; =70 , performance score 5070 exclusively due bone pain cause myeloma 18 year age old An expect survival great 3 month ANC &gt; 1,000/microliters , platelet count &gt; 100,000/microliters Donor patient must sign IRBapproved consent inform investigational nature study Donor must negative serology HIV Available haploidentical family donor fit undergo leukapheresis mismatch KIRligand ( ) patient graftversus host direction . Stored cell autografting least 30 million CD34+ cells/kg Backup cell least 20 million CD34+ cells/kg case nonengraftment . There must unambiguous marker response therapy first ten patient . Therefore patient must detectable quantifiable Mprotein light chain excretion urine , light chain quantification serum ( FREELITE ) clear radiological signal lesion ( ) order eligible After 10 relapse patient treated toxicity deem acceptable , highrisk myeloma ( define presence abnormal cytogenetics metaphase analysis ) patient without relapse enter Intravenous chemotherapy antibody therapy affect Tlymphocytes and/or natural killer cell e.g . cyclophosphamide , melphalan , ATG , Campath1H etc . within past 2 week prior commencement conditioning . Last therapy less 14 day prior start fludarabine Fever active infection , require IV antibiotic Liver function : total bilirubin &gt; 2xULN AST/ALT &gt; 3xULN Renal function : patient dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Transplant</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Donor</keyword>
	<keyword>Stem Cell</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Adriamycin</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Etoposide</keyword>
	<keyword>Melphalan</keyword>
</DOC>